Hanx Biopharmaceuticals (Wuhan) Co Ltd

03378

Company Profile

  • Business description

    Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.

  • Contact

    No. 1 Jiufeng 1st Road
    Building A8, Phase II, Bio-Innovation Park
    East Lake New Technology Development Zone
    Hubei
    Wuhan
    CHN

    T: +86 2765524978

    http://www.hanxbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    55

Stocks News & Analysis

stocks

Avoid this overvalued ASX lithium producer

Why the market may be overpricing future earnings for this lithium producer.
stocks

Morningstar's verdict on SpaceX

Mark and Shani run through the business and what our analysts think about the IPO.
stocks

More problems for WiseTech

Our view of police investigation into chairman Richard White.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,012.6010.700.12%
CAC 408,385.4944.780.54%
DAX 4024,740.36153.22-0.62%
Dow JONES (US)51,870.89204.050.39%
FTSE 10010,461.6332.780.31%
HKSE23,412.1875.900.33%
NASDAQ25,403.91183.13-0.72%
Nikkei 22569,174.97613.41-0.88%
NZX 50 Index13,400.6635.11-0.26%
S&P 5007,346.4019.06-0.26%
S&P/ASX 2008,808.407.000.08%
SSE Composite Index4,110.814.560.11%

Market Movers